Skip to main content

Specialty Pharmacy

  • FDA OKs continued compounding of versions of Makena

    SILVER SPRING, Md. — Usually, when the Food and Drug Administration approves a commercial version of a drug, it prohibits compounding pharmacies from producing it, but it’s making an exception in the case of a drug used to prevent premature births.

  • MedPro Rx makes Facebook debut

    RALEIGH, N.C. — A specialty infusion pharmacy has joined the social media realm.

    MedPro Rx's president, Nancy McFarlane, said that the company has launched a Facebook page, which will share MedPro Rx’s news, updates, blog posts and photos with its community. Additionally, the page will expand the company's online presence and customer service focus for clients, healthcare consumers, providers and third-party payers, McFarlane said.

  • Amanda Brown named BioPlus' Rx coordinators director

    ALTAMONTE SPRINGS, Fla. — BioPlus Specialty Pharmacy has promoted its supervisor of Rx coordinators.

    Amanda Brown, who joined the company in 2003, now will serve as director of Rx coordinators. In this role, she will manage and train BioPlus' sales team, but also will be involved in building business relationships with prescribers, achieving territorial goals and maximizing potential revenue for BioPlus.

  • Valeant seeks to buy Cephalon

    MISSISSAUGA, Ontario — Canadian drug maker Valeant Pharmaceuticals has proposed to buy Cephalon for $5.7 billion, Valeant said Tuesday.

    The buyout offer, equal to $73 per share, includes a 29% premium over Cephalon’s stock price. Valeant noted it had made previous offers, but was “disappointed by Cephalon’s unwillingness to engage in discussions in a timely manner.”

  • Drug shortages continue to rise, report finds

    NEW YORK — For many patients, the inability to pay for drugs is enough of a problem, but what if the drugs they need aren’t available at all?

    According to a new report by the Premier Healthcare Alliance, more than 240 drugs were hard to find or entirely unavailable, while more than 400 generic versions of branded drugs were backordered for more than five days. Premier said shortages had more than tripled since 2005, with the frequency and effects rising to critical levels and affecting all segments of health care.

  • ISPC to DoD: Reject exclusive networks in TPharm

    NEW YORK — A group representing specialty pharmacies is calling on the Department of Defense to not use exclusive networks in the Tricare pharmacy program.

    The Independent Specialty Pharmacy Coalition said exclusive arrangements for the program, also known as TPharm, were anti-competitive and harmful to patients who rely on specialty care by reducing patient choice and disrupting the continuum of care for them, and that reductions in pharmaceutical costs would not necessarily reduce overall healthcare spending.

  • FDA approves Bristol's cancer drug

    SILVER SPRING, Md. — The Food and Drug Administration has approved a new treatment for late-stage skin cancer, the agency said Friday.

    The FDA approved Bristol-Myers Squibb’s Yervoy (ipilimumab) for patients with melanoma that has spread to other parts of the body, also known as metastasis. More than 68,000 new cases of melanoma were diagnosed in the United States in 2010, and about 8,700 died from it, according to the National Cancer Institute, part of the National Institutes of Health.

  • DAW Rxs drive up healthcare costs, study finds

    WOONSOCKET, R.I. — "Dispense-as-written" prescriptions are exacerbating medication nonadherence and costing the U.S. healthcare system billions of dollars, according to a new study by researchers at Harvard University, Brigham and Women's Hospital, and CVS Caremark.

X
This ad will auto-close in 10 seconds